Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Clinical Trials of Vitamin E Supplementation and Risk for All-Cause Mortality, Ordered by Dosage of.

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 A No. at risk T T T

Advertisements

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Quantitative Synthesis II Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for Systematic Reviews Methods Guide

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

חזק בהגנה לבבית Valsartan in Heart Failure

Introduction to the Design and Analysis of Trials can be found on: Observational Studies.

E By Caleb Sawyer, MD Faculty Advisor: Kelly Mitchell, MD.

Vitamin E natural compounds Alpha-Tocopherol a.k.a. Vitamin E.

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

Quartiles of complete blood count components Jeffrey L. Anderson, et al. Am J Cardiol 2007;99:

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

Which Beta-Blocker is Best for Patients with Heart Failure? Summary and Comment by Joel M. Gore, MD Published in Journal Watch Cardiology December 17,

Shalev V, et al. Arch Intern Med 2009; 169:

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

Flow diagram of study selection process CAB: Commonwealth Agricultural Bureau Ethan M. Balk, et al. Arch Intern Med. 2007;167:21-30.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

Wald DS, et al. Am J Med 2009;122: Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:

Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.

Date of download: 6/2/2016 From: Quantitative Synthesis in Systematic Reviews Ann Intern Med. 1997;127(9): doi: /

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effectiveness of Foot Orthoses to Treat Plantar Fasciitis:

Date of download: 6/24/2016 From: Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality Ann Intern Med. 2005;142(1):37-46.

The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.

Columbia / CRF DES vs. BMS Meta-Analysis Kirtane et al, Circ 2009;119:

Date of download: 9/16/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cranberry-Containing Products for Prevention of Urinary.

Date of download: 9/17/2016 From: Dose Response to Vitamin D Supplementation in Postmenopausal Women: A Randomized Trial Ann Intern Med. 2012;156(6):

Copyright © 2013 American Medical Association. All rights reserved.

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Baseline Demographic and Clinic Variables According to Office vs 24-Hour or Home BP Giuseppe Mancia, et al. Hypertension 2006;47;

Ann Intern Med. 2009;150(11): doi: / Figure Legend:

From: Quantitative Synthesis in Systematic Reviews

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Filming: 15th of Febuary 2016, London, UK

Summary of Design Aim: Effect of Ramipril (up to 10mg/d) or Vit E (400 IU/d) vs its placebo on CV death, M I or stroke (primary) Design: Randomized double.

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

Adjusted relative mortality risk

PREMIER: Rate of hypertension at 18 months

Association between highest tertile for homocysteine and mortality

Nat. Rev. Cardiol. doi: /nrcardio

Risk of major congenital malformations among study infants according to fetal exposure to antihypertensives during first trimester alone* Variable ACE.

David J.A. Jenkins et al. JACC 2018;71:

Cystatin C levels and risk of death from all causes

Risk for BMI outcome (%)

Mintu P. Turakhia et al. JACEP 2016;2:

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Enrollment and Outcomes

Patient characteristics: American vs Canadian transplant patients

Baseline Characteristics of the Subjects

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Characteristics of Study Subjects and Events, According to the Quintile of Exposure to Fine Particulate Matter (PM2.5)* - Part I Kristin A. Miller et al.

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

David J.A. Jenkins et al. JACC 2018;71:

A Single Participant Exposed Twice to an Inflammatory Stimulus

Adjusted relative risk Adjusted odds ratio

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

David J.A. Jenkins et al. JACC 2018;71:

David J.A. Jenkins et al. JACC 2018;71:

Risk of cardiovascular disease mortality by cardiorespiratory fitness and body mass index categories, 2316 men with type 2 diabetes at baseline, 179 deaths.

Presentation transcript:

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Clinical Trials of Vitamin E Supplementation and Risk for All-Cause Mortality, Ordered by Dosage of Vitamin E

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Clinical Trials of Vitamin E Supplementation and Risk for All-Cause Mortality, Ordered by Dosage of Vitamin E

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Risk difference in all-cause mortality for randomized, controlled trials of vitamin E supplementation and pooled results for low-dosage (<400 IU/d) and high-dosage (400 IU/d) vitamin E trials

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Dose-response relationship between vitamin E supplementation and all-cause mortality in randomized, controlled trials

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Pooled All-Cause Mortality Risk Differences and Risk Ratios for Selected Vitamin E Dosages (Effect estimates were derived from quadratic-linear dose-response models Risk differences are shown as deaths per persons)

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Risk difference in all-cause mortality for randomized, controlled trials of vitamin E supplementation and pooled results for low-dosage (<400 IU/d) and high-dosage (400 IU/d) vitamin E trials on the basis of 4-way analyses of trials that used a factorial design

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Pooled All-Cause Mortality Risk Differences and Risk Ratios for Low-Dosage (<400 IU/d) and High-Dosage (400 IU/d) Vitamin E Trials Adjusted for Study-Specific Variables (Risk differences are shown as deaths per persons)